Clinical trial
Nasally Delivered Pulmozyme for Sinusitis in Cystic Fibrosis
NCT00416182 · University of Vermont, Other · Completed
Key facts
| NCT number | NCT00416182 |
|---|---|
| Title | Nasally Delivered Pulmozyme for Sinusitis in Cystic Fibrosis |
| Official title | The Use of Nasally Delivered Pulmozyme in the Treatment of Sinusitis in Cystic Fibrosis Patients: A Pilot Study |
| Lead sponsor | University of Vermont, Other |
| Collaborators | Genentech, Inc. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Sinusitis, Cystic Fibrosis |
| Intervention type | Drug |
| Interventions | Pulmozyme (dornase alfa), Placebo |
| Enrollment | 16 |
| Start date | Dec 1, 2006 |
| Primary completion | Jun 1, 2012 |
| Completion | Jun 1, 2012 |
| First posted | Dec 27, 2006 |
| Last update posted | Nov 14, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: